Potential treatments for relapsing remitting MS
Phase 3
Daclizumab
Daclizumab is an injectable drug that can reduce the number of immune cells in the body.
Ocrelizumab
Ocrelizumab is an intravenous infusion that targets cells of the immune system.
Cladribine
Cladribine is an oral medication that works by reducing the number of immune cells in the body.
RPC1063
RPC1063 is an oral medication thought to prevent a subset of immune cells from entering the brain and spinal cord.
Laquinimod
Laquinimod is a tablet that is thought to stop immune cells reaching the brain.
Ponesimod
Ponesimod is an oral treatment that might stop immune cells reaching the brain.
Ofatumumab
Ofatumumab is an injectable drug that can alter the behaviour of certain immune cells.
Phase 2
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
ATX-MS-1467
ATX-MS-1467 is an injection that aims to 'switch off' the immune system's attack on myelin.
Minocycline
Minocycline is an oral antibiotic currently used to treat bacterial infections and can prevent inflammation.
Raltegravir
Raltegravir is an oral antiretroviral drug that can fight viral infections.
Amiselimod
Amiselimod is an oral treatment that alters the behavior of immune cells.
Lipoic acid
Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain.
Clemastine
Clemastine is an oral treatment that has been shown to suppress the immune system and may promote myelin repair.
ATL1102
ATL1102 is an injection that prevents immune cells from reaching the brain and spinal cord.
Vatelizumab
Vatelizumab is an infusion that prevents certain immune cells from building up at sites of inflammation in MS.
Rituximab - development terminated
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Back to top
Potential treatments for primary progressive MS
Phase 3
Ocrelizumab
Ocrelizumab is an intravenous infusion that targets cells of the immune system.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
Masitinib
Masitinib is an oral treatment that blocks some of the body's immune responses.
Fingolimod
Fingolimod is an oral treatment that stops certain immune cells from reaching the brain.
Phase 2
Fluoxetine
Fluoxetine is a licensed medication in the treatment of depression. It is also currently being tested for people with primary and secondary progressive MS.
Ibudilast
Ibudilast (also known as MN-166) is a tablet thought to reduce inflammation and to protect against cell death, which could help to reduce nerve cell loss in MS.
Laquinimod
Laquinimod is a tablet that is thought to stop immune cells reaching the brain.
Natalizumab
Also known as Tysabri, natalizumab prevents immune cells from leaving the blood stream and entering the brain and spinal cord.
Rituximab - development terminated
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Back to top
Potential treatments for secondary progressive MS
Phase 3
Siponimod
Siponimod is an oral treatment that stops immune cells from reaching the brain.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
Masitinib
Masitinib is an oral treatment that blocks some of the body's immune responses.
Phase 2
MS-SMART
MS-SMART is a trial involving three oral treatments - amiloride, fluoxetine and riluzole - that have been shown to have neuroprotective properties.
Simvastatin
Simvastatin is an oral treatment that has been shown to have neuroprotective properties.
Riluzole
Riluzole is a licensed medication for motor neurone disease (MND). It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Amiloride
Amiloride is a licensed medication in the treatment of heart disease. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Fluoxetine
Fluoxetine is a licensed medication in the treatment of depression. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
MIS416
MIS416 is an infusion that is thought to alter the behaviour of certain immune cells in MS.
Tcelna
Tcelna is an injectable treatment that uses a person's own immune cells to alter the behaviour of the immune system in MS
Lipoic acid
Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain.
Ibudilast
Ibudilast (also known as MN-166) is a tablet thought to have anti-inflammatory effects and to protect against cell death, which may be beneficial in reducing nerve cell loss in MS.
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
Natalizumab
Also known as Tysabri, natalizumab prevents immune cells from leaving the blood stream and entering the brain and spinal cord.
Rituximab - development terminated
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Back to top
Potential treatments for optic neuritis
Phenytoin
Phenytoin is an oral treatment that has been shown to have the potential to protect nerve cells in the brain and spinal cord.
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
Amiloride
Amiloride is a licenced medication in the treatment of heart disease. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS, and has been trialled as a treatment for optic neuritis.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
https://www.mssociety.org.uk/ms-researc ... e-pipeline
Και για λεπτομέρειες για κάθε ουσία ξεχωριστά μπείτε στο άρθρο και πατήστε πάνω στο όνομα.
Phase 3
Daclizumab
Daclizumab is an injectable drug that can reduce the number of immune cells in the body.
Ocrelizumab
Ocrelizumab is an intravenous infusion that targets cells of the immune system.
Cladribine
Cladribine is an oral medication that works by reducing the number of immune cells in the body.
RPC1063
RPC1063 is an oral medication thought to prevent a subset of immune cells from entering the brain and spinal cord.
Laquinimod
Laquinimod is a tablet that is thought to stop immune cells reaching the brain.
Ponesimod
Ponesimod is an oral treatment that might stop immune cells reaching the brain.
Ofatumumab
Ofatumumab is an injectable drug that can alter the behaviour of certain immune cells.
Phase 2
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
ATX-MS-1467
ATX-MS-1467 is an injection that aims to 'switch off' the immune system's attack on myelin.
Minocycline
Minocycline is an oral antibiotic currently used to treat bacterial infections and can prevent inflammation.
Raltegravir
Raltegravir is an oral antiretroviral drug that can fight viral infections.
Amiselimod
Amiselimod is an oral treatment that alters the behavior of immune cells.
Lipoic acid
Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain.
Clemastine
Clemastine is an oral treatment that has been shown to suppress the immune system and may promote myelin repair.
ATL1102
ATL1102 is an injection that prevents immune cells from reaching the brain and spinal cord.
Vatelizumab
Vatelizumab is an infusion that prevents certain immune cells from building up at sites of inflammation in MS.
Rituximab - development terminated
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Back to top
Potential treatments for primary progressive MS
Phase 3
Ocrelizumab
Ocrelizumab is an intravenous infusion that targets cells of the immune system.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
Masitinib
Masitinib is an oral treatment that blocks some of the body's immune responses.
Fingolimod
Fingolimod is an oral treatment that stops certain immune cells from reaching the brain.
Phase 2
Fluoxetine
Fluoxetine is a licensed medication in the treatment of depression. It is also currently being tested for people with primary and secondary progressive MS.
Ibudilast
Ibudilast (also known as MN-166) is a tablet thought to reduce inflammation and to protect against cell death, which could help to reduce nerve cell loss in MS.
Laquinimod
Laquinimod is a tablet that is thought to stop immune cells reaching the brain.
Natalizumab
Also known as Tysabri, natalizumab prevents immune cells from leaving the blood stream and entering the brain and spinal cord.
Rituximab - development terminated
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Back to top
Potential treatments for secondary progressive MS
Phase 3
Siponimod
Siponimod is an oral treatment that stops immune cells from reaching the brain.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
Masitinib
Masitinib is an oral treatment that blocks some of the body's immune responses.
Phase 2
MS-SMART
MS-SMART is a trial involving three oral treatments - amiloride, fluoxetine and riluzole - that have been shown to have neuroprotective properties.
Simvastatin
Simvastatin is an oral treatment that has been shown to have neuroprotective properties.
Riluzole
Riluzole is a licensed medication for motor neurone disease (MND). It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Amiloride
Amiloride is a licensed medication in the treatment of heart disease. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
Fluoxetine
Fluoxetine is a licensed medication in the treatment of depression. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS.
MIS416
MIS416 is an infusion that is thought to alter the behaviour of certain immune cells in MS.
Tcelna
Tcelna is an injectable treatment that uses a person's own immune cells to alter the behaviour of the immune system in MS
Lipoic acid
Lipoic acid is an oral treatment that may prevent immune cells from reaching the brain.
Ibudilast
Ibudilast (also known as MN-166) is a tablet thought to have anti-inflammatory effects and to protect against cell death, which may be beneficial in reducing nerve cell loss in MS.
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
Natalizumab
Also known as Tysabri, natalizumab prevents immune cells from leaving the blood stream and entering the brain and spinal cord.
Rituximab - development terminated
Rituximab is an intravenous infusion that can reduce the number of immune cells in the body.
Back to top
Potential treatments for optic neuritis
Phenytoin
Phenytoin is an oral treatment that has been shown to have the potential to protect nerve cells in the brain and spinal cord.
Anti-LINGO-1
Anti-LINGO-1 is an intravenous infusion treatment that has been shown to have the potential to repair myelin.
Amiloride
Amiloride is a licenced medication in the treatment of heart disease. It is also currently being tested in a phase 2 clinical trial called MS-SMART in people with secondary progressive MS, and has been trialled as a treatment for optic neuritis.
MD1003
MD1003 is an oral medication that has shown the potential to promote myelin repair.
https://www.mssociety.org.uk/ms-researc ... e-pipeline
Και για λεπτομέρειες για κάθε ουσία ξεχωριστά μπείτε στο άρθρο και πατήστε πάνω στο όνομα.
IT IS THE WAY OF THE WARRIOR TO FIGHT SUPERIOR ODDS
